Literature DB >> 28534711

Expressions of irisin and urotensin II and their relationships with blood pressure in patients with preeclampsia.

Li-Jie Zhang1, Qian Xie1, Chao-Shu Tang2, Ai-Hua Zhang1.   

Abstract

The aims of this study are to observe irisin and urotensin II (UII) levels in serum and placenta in normal pregnant and preeclamptic women and investigate the relationship between expressions irisin and UII, and their association with blood pressure. A total of 67 pregnant subjects were recruited, including 31 healthy and 36 preeclamptic pregnant women. Serum irisin and UII concentrations were measured. Expressions of fibronectin type III domain-containing protein 5 (FNDC5) (irisin precursor) and UII in placenta specimens were performed. There was no significant difference of serum irisin levels between severe preeclamptic (SPE)) patients, mild preeclamptic (MPE) patients and normal controls, while serum UII was significantly higher in preeclamptic women than normal pregnancy. There was no relationship between serum UII and irisin levels. In patients with preeclampsia, serum irisin was negatively associated with systolic and diastolic blood pressure(r = -0.350, P = 0.004, r = -0.307, P = 0.011), while serum UII was positively associated with systolic blood pressure (r = 0.291, P = 0.031). Serum irisin, UII, urinary protein level, BMI and serum creatinine were the independent determinants of blood pressure in preeclampsia by multiple regression analysis. Protein expression of FNDC5 and UII was upregulated in placenta of patients with SPE and positively correlated with systolic blood pressure and urinary protein level. We firstly verify that serum irisin and placental irisin precursor expressions have differently correlated with blood pressure. Expressions of irisin and urotensin II have relationships with blood pressure in patients with preeclampsia.

Entities:  

Keywords:  Blood pressure; irisin; placenta; preeclampsia; pregnancy; urotensin II

Mesh:

Substances:

Year:  2017        PMID: 28534711     DOI: 10.1080/10641963.2016.1273945

Source DB:  PubMed          Journal:  Clin Exp Hypertens        ISSN: 1064-1963            Impact factor:   1.749


  8 in total

Review 1.  Lifestyle interventions for the prevention and treatment of hypertension.

Authors:  Pedro L Valenzuela; Pedro Carrera-Bastos; Beatriz G Gálvez; Gema Ruiz-Hurtado; José M Ordovas; Luis M Ruilope; Alejandro Lucia
Journal:  Nat Rev Cardiol       Date:  2020-10-09       Impact factor: 32.419

Review 2.  Prenatal exercise in fetal development: a placental perspective.

Authors:  Song Ah Chae; Jun Seok Son; Min Du
Journal:  FEBS J       Date:  2021-09-12       Impact factor: 5.622

3.  Fibronectin type III domain-containing 5 in cardiovascular and metabolic diseases: a promising biomarker and therapeutic target.

Authors:  Xin Zhang; Can Hu; Hai-Ming Wu; Zhen-Guo Ma; Qi-Zhu Tang
Journal:  Acta Pharmacol Sin       Date:  2020-11-19       Impact factor: 7.169

4.  The Role of Myokines and Adipokines in Hypertension and Hypertension-related Complications.

Authors:  Ken Chen; Mengdi Zhou; Xiaomei Wang; Shuang Li; Dachun Yang
Journal:  Hypertens Res       Date:  2019-05-27       Impact factor: 3.872

Review 5.  The Emerging Role of Irisin in Cardiovascular Diseases.

Authors:  Jinjuan Fu; Fangtang Li; Yuanjuan Tang; Lin Cai; Chunyu Zeng; Yongjian Yang; Jian Yang
Journal:  J Am Heart Assoc       Date:  2021-10-08       Impact factor: 5.501

6.  Irisin Protects the Human Placenta from Oxidative Stress and Apoptosis via Activation of the Akt Signaling Pathway.

Authors:  Hamid-Reza Kohan-Ghadr; Brooke Armistead; Mikaela Berg; Sascha Drewlo
Journal:  Int J Mol Sci       Date:  2021-10-18       Impact factor: 5.923

Review 7.  Irisin, an Effective Treatment for Cardiovascular Diseases?

Authors:  Chen Liu; Aili Wei; Tianhui Wang
Journal:  J Cardiovasc Dev Dis       Date:  2022-09-13

8.  Irisin Maternal Plasma and Cord Blood Levels in Mothers with Spontaneous Preterm and Term Delivery.

Authors:  Tereza Pavlova; Filip Zlamal; Josef Tomandl; Zuzana Hodicka; Sumeet Gulati; Julie Bienertova-Vasku
Journal:  Dis Markers       Date:  2018-05-28       Impact factor: 3.434

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.